AtriCure, Inc. is a medical device company that develops, manufactures and sells cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue. The Company's primary product line, which accounts for a majority of its revenues, is the AtriCure Isolator system. AtriCure's Isolator system consists primarily of a compact power generator known as an ablation and sensing unit (ASU), a switchbox unit (ASB), which allows physicians to toggle between multiple products and multiple configurations of its Isolator clamps, including its Isolator Synergy clamps. AtriCure also sells a multifunctional bipolar pen, or multifunctional pen, which is often used by physicians in combination with its Isolator system to ablate cardiac tissue and for temporary pacing, sensing, stimulating and recording during the evaluation of cardiac arrhythmias. In 2008, The Company received FDA approval for its EXCLUDE clinical trial.